Literature DB >> 33343255

New Tools for Implementing Evidence-Based Care for Serious Mental Illness.

Amy N Cohen1, Tristan Gorrindo1.   

Abstract

More than 11 million adults in the United States have a serious mental illness. Outcomes for these illnesses are good when appropriate treatments are received; however, rates of delivery and utilization of evidence-based care for this population are moderate to low. This article introduces SMI Adviser, a national initiative, supported by the Substance Abuse and Mental Health Services Administration, to advance the use of evidence-based practices and delivery of patient-centered care for the population with serious mental illness. SMI Adviser offers free technical assistance to clinicians caring for this population through accredited educational opportunities, vetted resources, and on-demand consultations.
Copyright © by the American Psychiatric Association.

Entities:  

Keywords:  Affective disorders; evidence-based practices; quality of care; schizophrenia; serious mental illness

Year:  2020        PMID： 33343255      PMCID： PMC7725150          DOI： 10.1176/appi.focus.20200023

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN： 1541-4094


  11 in total

Review 1.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos
Journal:  Lancet       Date:  2013-08-29       Impact factor: 79.321

Review 2.  Psychiatric Advance Directives: Origins, Benefits, Challenges, and Future Directions.

Authors:  Heather Murray; Hal S Wortzel
Journal:  J Psychiatr Pract       Date:  2019-07       Impact factor: 1.325

3.  Psychiatric advance directives and reduction of coercive crisis interventions.

Authors:  Jeffrey W Swanson; Marvin S Swartz; Eric B Elbogen; Richard A VAN Dorn; H Ryan Wagner; Lorna A Moser; Christine Wilder; Allison R Gilbert
Journal:  J Ment Health       Date:  2008-01-01

Review 4.  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Authors:  Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

5.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

Authors:  Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

6.  Implementing evidence-based practices for people with schizophrenia.

Authors:  Robert E Drake; Gary R Bond; Susan M Essock
Journal:  Schizophr Bull       Date:  2009-06-02       Impact factor: 9.306

7.  Individual Placement And Support Services Boost Employment For People With Serious Mental Illnesses, But Funding Is Lacking.

Authors:  Robert E Drake; Gary R Bond; Howard H Goldman; Michael F Hogan; Mustafa Karakus
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

8.  Impact of psychiatric advance directive facilitation on mental health consumers: empowerment, treatment attitudes and the role of peer support specialists.

Authors:  Michele M Easter; Jeffrey W Swanson; Allison G Robertson; Lorna L Moser; Marvin S Swartz
Journal:  J Ment Health       Date:  2020-02-04

Review 9.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

10.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.